Fig. 9

The senolytic drug, ABT-263, has beneficial effects on normal age-related motor function but does not confer robust protection to acute TBI. (A) Experimental design. Naïve aged mice (18-month-old) were treated with ABT-263 (50 mg/kg) or vehicle (Veh) once daily for 2 weeks by oral gavage. After two-weeks on and one week off drug, mice were subjected to TBI up to 72 h post-injury. (B) Body weight was monitored before and at 2 weeks (wks) after the treatment. (C-H) A battery of neurobehavioral tests was performed to assess forelimb grip strength (C), time on rotarod (D), and CatWalk gait analysis for body speed (E), stride length (F), swing speed (G), and cadence (H). (I) Representative dot plots of immune populations in the ipsilateral (Ipsi) and contralateral (Contra) brain hemisphere at 72 h after TBI. (J-L) Quantification of CD45^intCD11b⁺ microglia, CD45^hiCD11b⁺-infiltrating myeloid cell, CD45^hiCD11b⁻-infiltrating lymphocytes counts per hemisphere are shown for Sham, TBI, treatment in aged mice. n = 9–10 mice/group. Data were analyzed using two-way ANOVA group analysis with Tukey’s test for multiple comparisons. ***p < 0.001, **p < 0.01, *p < 0.05. SH: Sham